Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.84 |
| ▸ | MEN1 | O00255 | 3/20 | 0.84 |
| ▸ | NPC1 | O15118 | 5/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | PPIA | P62937 | 2/20 | 0.53 |
| ▸ | PPIF | P30405 | 1/20 | 0.53 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5531567 | 0.84 | KMT2A (0.61) | KMT2AMEN1NPC1RAB9ALTA4H | |
| SCHEMBL488892 | 0.83 | KMT2A (0.68) | KMT2AMEN1NPC1RAB9AS1PR4 | |
| SCHEMBL26917116 | 0.83 | NPC1 (0.65) | KMT2AMEN1NPC1RAB9AS1PR4 | |
| SCHEMBL29857951 | 0.83 | NPC1 (0.65) | KMT2AMEN1NPC1RAB9AS1PR4 | |
| SCHEMBL26916583 | 0.83 | KMT2A (0.64) | KMT2AMEN1NPC1RAB9AS1PR4 | |
| SCHEMBL8566190 | 0.81 | KMT2A (0.58) | KMT2AMEN1NPC1RAB9ALTA4H | |
| SCHEMBL488659 | 0.80 | NPC1 (0.64) | KMT2AMEN1NPC1RAB9AS1PR4 | |
| SCHEMBL10560805 | 0.80 | KMT2A (0.60) | KMT2AMEN1NPC1RAB9AS1PR4 | |
| SCHEMBL10565139 | 0.80 | KMT2A (0.60) | KMT2AMEN1NPC1RAB9AS1PR4 | |
| SCHEMBL488438 | 0.80 | KMT2A (0.60) | KMT2AMEN1NPC1RAB9AS1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7109260-A | — | — | None | — | — | JP | disclosed |
| CN-114671867-B | Preparation method of tocartinib intermediate 7-hydroxy- [1,2,4] triazolo [1,5-a ] pyridine | 上海法默生物科技有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-114671867-A | Preparation method of 7-hydroxy- [1,2,4] triazolo [1,5-a ] pyridine serving as intermediate of tocainib | 上海法默生物科技有限公司 | 2022-06-28 | — | — | CN | disclosed |
| US-20140288086-A1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288086-A1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-8785632-B2 | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120263706-A1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. | 2012-10-18 | — | — | US | disclosed |
| US-8106197-B2 | Aminoheteroaryl compounds as protein kinase inhibitors | PFIZER INC. (US) | 2012-01-31 | — | — | US | disclosed |
| CN-101023064-B | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors | PFIZER | 2011-02-16 | — | — | CN | disclosed |
| US-7858643-B2 | Crizotinib, a c-Met protein kinase inhibitor anticancer agent; 3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine is crizotinib | AGOURON PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20050112770-A1 | Method for optical measurement of multi-stranded nucleic acid | FUJI PHOTO FILM CO., LTD. | 2005-05-26 | — | — | US | disclosed |
| EP-1362894-A2 | Method for optical measurement of multi-stranded nucleic acid using cyanine dyes | FUJI PHOTO FILM CO., LTD. (JP) | 2003-11-19 | — | — | EP | disclosed |
| EP-0735025-B1 | Process for producing aminonitropyridines | SUMITOMO CHEMICAL CO (JP) | 1998-07-01 | — | — | EP | disclosed |
| US-5648496-A | AMINATION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-07-15 | — | — | US | disclosed |
| EP-0735025-A1 | Process for producing aminonitropyridines | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-10-02 | — | — | EP | disclosed |
| JP-H07109260-A | PRODUCTION OF 5-AMINO-2-NITROPYRIDINE DERIVATIVE AND 5-DIAMOND-3-HYDROXYPYRIDINE DERIVATIVE | FUJI PHOTO FILM CO LTD | 1995-04-25 | — | — | JP | disclosed |
| US-4410530-A | CARDIO-SELECTIVE B-RECEPTOR BLOCKING AGENTS AND STIMULANTS | CIBA-GEIGY CORPORATION (US) | 1983-10-18 | — | — | US | disclosed |
| US-4195090-A | ADRENERGIC BLOCKING AGENTS | CIBA-GEIGY CORPORATION (US) | 1980-03-25 | — | — | US | disclosed |
| US-4115575-A | CARDIOVASCULAR DISORDERS | CIBA-GEIGY CORPORATION (US) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120263706-A1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | MET, MAP3K15, MAP3K1 | KMT2A 1159/4885MEN1 776/4885NPC1 2029/4885 |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP4K1, MAP4K2 | KMT2A 1170/4885MEN1 1141/4885NPC1 3437/4885 |
| US-20140288086-A1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | MET, MAP3K15, MAP3K1 | KMT2A 1159/4885MEN1 776/4885NPC1 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.